- sortMedia focus
- auth
- source:
- pubDate2020-11-18 16:12
- Visitas:
[Descripción resumida]Pay attention to R & D investment and increase development momentum
Recently, the new office building of nearly 4000 square meters and the R & D center of 1300 square meters of Zhejiang Kangmu Pharmaceutical Co., Ltd. have been put into use, further improving the R & D capacity and office environment of the company's API.
"The new office building is conducive to the exchange of technology and technology and the introduction of talents." Yao yu'e, director of Human Resources Department of Zhejiang Kangmu Pharmaceutical Co., Ltd., introduced that now the company's new R & D center has been put into use, and four new products have entered the stage of small-scale test and pilot test. It is expected that the output value will increase by 15% year-on-year this year.
It is understood that Kangmu pharmaceutical attached great importance to R & D at the beginning of its establishment and adhered to "scientific and technological innovation". Now it has three research institutes, namely API Research Institute, preparation research institute and Analysis Research Institute. It is a comprehensive modern animal health enterprise integrating the R & D, production and sales of veterinary API and preparation. Among them, chlorfenicol and tilmicosin series APIs are the designated production units of the Ministry of agriculture, and the products are also exported to many countries and regions such as the Americas, the Middle East and Southeast Asia. At present, the company has "Zhejiang agricultural science and technology R & D center" and "Shaoxing enterprise technology center".
With the change of the age structure of farmers, farmers are willing to try new things, and the research and development of new products has become the lifeline of Kangmu pharmaceutical industry. In recent years, the company's R & D investment has increased steadily, especially in the past two years. The R & D investment exceeded 14 million yuan in 2018 and 16 million yuan in 2019.
"The importance of R & D is obvious to all, so Kangmu pharmaceutical has always adhered to the independent R & D route." Yao yu'e told reporters that while constantly strengthening the construction of its own R & D system, the company also actively cultivates and introduces technical talents, and focuses on strengthening industry university research cooperation with well-known universities and research institutions to further enhance the company's technical strength.
Among them, Kangmu pharmaceutical's new process project with an annual output of 500 tons of florfenicol API has been listed as the "provincial spark project" by the Provincial Department of science and technology, and has been listed in the national torch plan. "Green production technology project of florfenicol to achieve energy conservation and emission reduction" has been listed in the key R & D plan of Zhejiang Province by the Provincial Department of science and technology.
At present, Kangmu pharmaceutical has established a good partnership with Zhejiang University, Zhejiang University of technology, Fudan University, Shanghai Sixin Biochemical Technology Co., Ltd., German Leibniz Catalytic Research Institute, China Pharmaceutical University, etc., providing strong technical support for the company's subsequent product development and process optimization.
At present, the veterinary medicine industry has a high technical content, which has high requirements for the personnel and equipment of enterprise R & D institutions. Since June, the Ministry of agriculture and animal husbandry has put forward the requirements for the reconstruction of veterinary drug production workshops and the relocation of veterinary drug production enterprises in rural areas, which meet the requirements of the Ministry of agriculture and animal husbandry.
"The state pays more and more attention to the safety of veterinary drug products, gradually improves the requirements for product stability, medicinal and ecological safety, and puts forward higher requirements for enterprise safety production and environmental protection." Yuan Qing, technical director of Zhejiang Kangmu Pharmaceutical Co., Ltd., said that recently, the company focused on the technical transformation of wastewater treatment early warning system and workshop automation control system, and also added high-efficiency centrifuges, high-efficiency distillation columns and other equipment, which is believed to provide stronger hardware support for the safe production of enterprises.
[Descripción resumida]Pay attention to R & D investment and increase development momentum
Recently, the new office building of nearly 4000 square meters and the R & D center of 1300 square meters of Zhejiang Kangmu Pharmaceutical Co., Ltd. have been put into use, further improving the R & D capacity and office environment of the company's API.
"The new office building is conducive to the exchange of technology and technology and the introduction of talents." Yao yu'e, director of Human Resources Department of Zhejiang Kangmu Pharmaceutical Co., Ltd., introduced that now the company's new R & D center has been put into use, and four new products have entered the stage of small-scale test and pilot test. It is expected that the output value will increase by 15% year-on-year this year.
It is understood that Kangmu pharmaceutical attached great importance to R & D at the beginning of its establishment and adhered to "scientific and technological innovation". Now it has three research institutes, namely API Research Institute, preparation research institute and Analysis Research Institute. It is a comprehensive modern animal health enterprise integrating the R & D, production and sales of veterinary API and preparation. Among them, chlorfenicol and tilmicosin series APIs are the designated production units of the Ministry of agriculture, and the products are also exported to many countries and regions such as the Americas, the Middle East and Southeast Asia. At present, the company has "Zhejiang agricultural science and technology R & D center" and "Shaoxing enterprise technology center".
With the change of the age structure of farmers, farmers are willing to try new things, and the research and development of new products has become the lifeline of Kangmu pharmaceutical industry. In recent years, the company's R & D investment has increased steadily, especially in the past two years. The R & D investment exceeded 14 million yuan in 2018 and 16 million yuan in 2019.
"The importance of R & D is obvious to all, so Kangmu pharmaceutical has always adhered to the independent R & D route." Yao yu'e told reporters that while constantly strengthening the construction of its own R & D system, the company also actively cultivates and introduces technical talents, and focuses on strengthening industry university research cooperation with well-known universities and research institutions to further enhance the company's technical strength.
Among them, Kangmu pharmaceutical's new process project with an annual output of 500 tons of florfenicol API has been listed as the "provincial spark project" by the Provincial Department of science and technology, and has been listed in the national torch plan. "Green production technology project of florfenicol to achieve energy conservation and emission reduction" has been listed in the key R & D plan of Zhejiang Province by the Provincial Department of science and technology.
At present, Kangmu pharmaceutical has established a good partnership with Zhejiang University, Zhejiang University of technology, Fudan University, Shanghai Sixin Biochemical Technology Co., Ltd., German Leibniz Catalytic Research Institute, China Pharmaceutical University, etc., providing strong technical support for the company's subsequent product development and process optimization.
At present, the veterinary medicine industry has a high technical content, which has high requirements for the personnel and equipment of enterprise R & D institutions. Since June, the Ministry of agriculture and animal husbandry has put forward the requirements for the reconstruction of veterinary drug production workshops and the relocation of veterinary drug production enterprises in rural areas, which meet the requirements of the Ministry of agriculture and animal husbandry.
"The state pays more and more attention to the safety of veterinary drug products, gradually improves the requirements for product stability, medicinal and ecological safety, and puts forward higher requirements for enterprise safety production and environmental protection." Yuan Qing, technical director of Zhejiang Kangmu Pharmaceutical Co., Ltd., said that recently, the company focused on the technical transformation of wastewater treatment early warning system and workshop automation control system, and also added high-efficiency centrifuges, high-efficiency distillation columns and other equipment, which is believed to provide stronger hardware support for the safe production of enterprises.
- sortMedia focus
- auth
- source:
- pubDate2020-11-18 16:12
- Visitas:
Pay attention to R & D investment and increase development momentum
Recently, the new office building of nearly 4000 square meters and the R & D center of 1300 square meters of Zhejiang Kangmu Pharmaceutical Co., Ltd. have been put into use, further improving the R & D capacity and office environment of the company's API.
"The new office building is conducive to the exchange of technology and technology and the introduction of talents." Yao yu'e, director of Human Resources Department of Zhejiang Kangmu Pharmaceutical Co., Ltd., introduced that now the company's new R & D center has been put into use, and four new products have entered the stage of small-scale test and pilot test. It is expected that the output value will increase by 15% year-on-year this year.
It is understood that Kangmu pharmaceutical attached great importance to R & D at the beginning of its establishment and adhered to "scientific and technological innovation". Now it has three research institutes, namely API Research Institute, preparation research institute and Analysis Research Institute. It is a comprehensive modern animal health enterprise integrating the R & D, production and sales of veterinary API and preparation. Among them, chlorfenicol and tilmicosin series APIs are the designated production units of the Ministry of agriculture, and the products are also exported to many countries and regions such as the Americas, the Middle East and Southeast Asia. At present, the company has "Zhejiang agricultural science and technology R & D center" and "Shaoxing enterprise technology center".
With the change of the age structure of farmers, farmers are willing to try new things, and the research and development of new products has become the lifeline of Kangmu pharmaceutical industry. In recent years, the company's R & D investment has increased steadily, especially in the past two years. The R & D investment exceeded 14 million yuan in 2018 and 16 million yuan in 2019.
"The importance of R & D is obvious to all, so Kangmu pharmaceutical has always adhered to the independent R & D route." Yao yu'e told reporters that while constantly strengthening the construction of its own R & D system, the company also actively cultivates and introduces technical talents, and focuses on strengthening industry university research cooperation with well-known universities and research institutions to further enhance the company's technical strength.
Among them, Kangmu pharmaceutical's new process project with an annual output of 500 tons of florfenicol API has been listed as the "provincial spark project" by the Provincial Department of science and technology, and has been listed in the national torch plan. "Green production technology project of florfenicol to achieve energy conservation and emission reduction" has been listed in the key R & D plan of Zhejiang Province by the Provincial Department of science and technology.
At present, Kangmu pharmaceutical has established a good partnership with Zhejiang University, Zhejiang University of technology, Fudan University, Shanghai Sixin Biochemical Technology Co., Ltd., German Leibniz Catalytic Research Institute, China Pharmaceutical University, etc., providing strong technical support for the company's subsequent product development and process optimization.
At present, the veterinary medicine industry has a high technical content, which has high requirements for the personnel and equipment of enterprise R & D institutions. Since June, the Ministry of agriculture and animal husbandry has put forward the requirements for the reconstruction of veterinary drug production workshops and the relocation of veterinary drug production enterprises in rural areas, which meet the requirements of the Ministry of agriculture and animal husbandry.
"The state pays more and more attention to the safety of veterinary drug products, gradually improves the requirements for product stability, medicinal and ecological safety, and puts forward higher requirements for enterprise safety production and environmental protection." Yuan Qing, technical director of Zhejiang Kangmu Pharmaceutical Co., Ltd., said that recently, the company focused on the technical transformation of wastewater treatment early warning system and workshop automation control system, and also added high-efficiency centrifuges, high-efficiency distillation columns and other equipment, which is believed to provide stronger hardware support for the safe production of enterprises.